Lyrica (Epilepsy) - Forecast and Market Analysis to 2022

GlobalData has released its new PharmaPoint Drug Evaluation report, “Lyrica (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Lyrica
is a compound with both analgesic and anticonvulsant properties that was developed by Pfizer as a more potent successor to gabapentin (Neurontin). Pregabalin is the active pharmaceutical ingredient in Lyrica, and it binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues. Blockade of these channels has been shown to inhibit the calcium-dependent release of a number of neurotransmitters. While pregabalin is a structural derivative of the inhibitory neurotransmitter GABA, it does not bind directly to GABA-A, GABA-B, or benzodiazepine receptors, and it does not augment GABA responses. Lyrica is available as both a capsule and solution for oral administration, and has been approved for the treatment of partial seizures, peripheral neuropathy (sensory neuropathy), fibromyalgia, postherpetic neuralgia (PHN), and diabetic neuropathy.

Scope

- Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on Lyrica including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for Lyrica for the top nine countries from 2012 to 2022.- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of Lyrica performance- Obtain sales forecast for Lyrica from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)
SHOW LESS
READ MORE >

1.2 List of FiguresFigure 1: Summary of the Pathophysiology of Seizures by Net Increased Neuronal ExcitationFigure 2: Mechanisms of Action of AEDs at the SynapseFigure 3: AED Selection Based on Comorbidity

PLEASE SELECT A FORMAT

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

EUR 6587USD 6,990GBP 4,631

SITE LICENSE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

EUR 9881USD 10,485GBP 6,946

ENTERPRISEWIDE Electronic (PDF)

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.